• Liran Levy, Ella Huszti, Jussi Tikkanen, Rasheed Ghany, William Klement, Musawir Ahmed, Shahid Husain, Pierre O Fiset, David Hwang, Shaf Keshavjee, Lianne G Singer, Stephen Juvet, and Tereza Martinu.
• Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada.
• Am. J. Transplant. 2020 Jan 1; 20 (1): 241-249.

AbstractAcute cellular rejection (ACR) is a significant risk factor for chronic lung allograft dysfunction (CLAD). Although clinically manifest and higher grade (≥A2) ACR is generally treated with augmented immunosuppression, management of minimal (grade A1) ACR remains controversial. In our program, patients with subclinical and spirometrically stable A1 rejection (StA1R) are routinely not treated with augmented immunosuppression. We hypothesized that an untreated first StA1R does not increase the risk of CLAD or death compared to episodes of spirometrically stable no ACR (StNAR). The cohort was drawn from all consecutive adult, first, bilateral lung transplantations performed between 1999 and 2017. Biopsies obtained in the first-year posttransplant were paired with (forced expiratory volume in 1 second FEV1 ). The first occurrence of StA1R was compared to a time-matched StNAR. The risk of CLAD or death was assessed using univariable and multivariable Cox proportional hazards models. The analyses demonstrated no significant difference in risk of CLAD or death in patients with a first StA1R compared to StNAR. This largest study to date shows that, in clinically stable patients, an untreated first A1 ACR in the first-year posttransplant is not significantly associated with an increased risk for CLAD or death. Watchful-waiting approach may be an acceptable tactic for stable A1 episodes in lung transplant recipients.© 2019 The American Society of Transplantation and the American Society of Transplant Surgeons.

34 keywords...

hide…